<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(26)</volume><submitter>Feng L</submitter><pubmed_abstract>&lt;i>Background&lt;/i>: Metformin, an antidiabetic drug, has been reported to be involved in atherosclerosis (AS). In this study, the effects of metformin on oxidized low-density lipoprotein (Ox-LDL)-induced macrophage apoptosis were investigated, and the mechanisms involved in this process were examined. &lt;i>Methods&lt;/i>: qRT-qPCR analysis was performed to detect the expression of miR-34a in macrophage cells. Cell proliferation was determined by MTT assays and colony formation assays. Cell apoptosis was assessed by the detection of apoptotic rate and caspase 3 activity. Western blot analysis was performed to evaluate the expression of Bcl2 protein. &lt;i>Results&lt;/i>: Metformin treatment promoted proliferation and suppressed apoptosis in macrophages following the treatment of oxidized low-density lipoprotein (Ox-LDL). Metformin could inhibit miR-34a in macrophages. miR-34a overexpression could reverse the effect of metformin on proliferation and apoptosis in Ox-LDL-treated macrophages. Moreover, metformin could increase the expression of the miR-34a target gene Bcl2. Furthermore, metformin treatment exerted the pro-proliferation and anti-apoptosis effect through regulating Bcl2 expression in Ox-LDL-stimulated macrophages. &lt;i>Conclusion&lt;/i>: Metformin facilitated proliferation and inhibited apoptosis of macrophages treated with Ox-LDL through the miR-34a/Bcl2 axis, indicating the potential value of metformin in AS therapy.</pubmed_abstract><journal>RSC advances</journal><pagination>14670-14676</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9064147</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Metformin promotes proliferation and suppresses apoptosis in Ox-LDL stimulated macrophages by regulating the miR-34a/Bcl2 axis.</pubmed_title><pmcid>PMC9064147</pmcid><pubmed_authors>Liu X</pubmed_authors><pubmed_authors>Feng L</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Mei X</pubmed_authors><pubmed_authors>Huang H</pubmed_authors><pubmed_authors>Xiao W</pubmed_authors><pubmed_authors>Tian S</pubmed_authors><pubmed_authors>Liu T</pubmed_authors><pubmed_authors>Shi J</pubmed_authors><pubmed_authors>Bai Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Metformin promotes proliferation and suppresses apoptosis in Ox-LDL stimulated macrophages by regulating the miR-34a/Bcl2 axis.</name><description>&lt;i>Background&lt;/i>: Metformin, an antidiabetic drug, has been reported to be involved in atherosclerosis (AS). In this study, the effects of metformin on oxidized low-density lipoprotein (Ox-LDL)-induced macrophage apoptosis were investigated, and the mechanisms involved in this process were examined. &lt;i>Methods&lt;/i>: qRT-qPCR analysis was performed to detect the expression of miR-34a in macrophage cells. Cell proliferation was determined by MTT assays and colony formation assays. Cell apoptosis was assessed by the detection of apoptotic rate and caspase 3 activity. Western blot analysis was performed to evaluate the expression of Bcl2 protein. &lt;i>Results&lt;/i>: Metformin treatment promoted proliferation and suppressed apoptosis in macrophages following the treatment of oxidized low-density lipoprotein (Ox-LDL). Metformin could inhibit miR-34a in macrophages. miR-34a overexpression could reverse the effect of metformin on proliferation and apoptosis in Ox-LDL-treated macrophages. Moreover, metformin could increase the expression of the miR-34a target gene Bcl2. Furthermore, metformin treatment exerted the pro-proliferation and anti-apoptosis effect through regulating Bcl2 expression in Ox-LDL-stimulated macrophages. &lt;i>Conclusion&lt;/i>: Metformin facilitated proliferation and inhibited apoptosis of macrophages treated with Ox-LDL through the miR-34a/Bcl2 axis, indicating the potential value of metformin in AS therapy.</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 May</publication><modification>2025-04-04T12:43:21.965Z</modification><creation>2025-04-04T12:43:21.965Z</creation></dates><accession>S-EPMC9064147</accession><cross_references><pubmed>35516319</pubmed><doi>10.1039/c9ra00705a</doi></cross_references></HashMap>